Evidence map›Paper›PMID 36362805›Full record

ArticleJournal of clinical medicine2022

Clinical Outcomes and Prevalence of Sarcopenia in Patients with Moderate to Severe COVID-19.

Shuhei Yamamoto, Yasunari Sakai, Keiji Matsumori, Ryuji Osawa, Shun Ito, Daichi Tsukakoshi, Tomoki Ohno, Hiroaki Ohta, Takashi Ichiyama, Masamichi Komatsu and 4 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shuhei YamamotoDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.ORCID 0000-0003-0257-633X
Yasunari SakaiDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Keiji MatsumoriDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Ryuji OsawaDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Shun ItoDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Daichi TsukakoshiDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.ORCID 0000-0003-0771-325X
Tomoki OhnoDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Hiroaki OhtaDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Takashi IchiyamaDepartment of Intensive Care Unit, Shinshu University Hospital, Nagano 390-8621, Japan.ORCID 0000-0002-1962-6738
Masamichi KomatsuFirst Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan.ORCID 0000-0002-1228-1490
Yosuke WadaFirst Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan.ORCID 0000-0003-3349-2980
Masayuki HanaokaFirst Department of Internal Medicine, Shinshu University School of Medicine, Nagano 390-8621, Japan.
Shota IkegamiDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.
Hiroshi HoriuchiDepartment of Rehabilitation, Shinshu University Hospital, Nagano 390-8621, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The purpose of this study was to investigate the effectiveness and clinical outcomes of inpatient rehabilitation for patients with severe COVID-19 in Japan. Methods: Patients with severe COVID-19 who underwent rehabilitation during hospitalization were included. The Medical Research Council (MRC) score and short physical performance battery (SPPB), such as physical function assessment and the intensive care unit (ICU) mobility scale, the functional status score for the ICU, and Barthel index as activities of daily living (ADLs) were evaluated at admission and discharge or transfer from the hospital. The correlation between SPPB at discharge and each factor at admission were also analyzed. Furthermore, the prevalence of sarcopenia was evaluated by defining SPPB of <9 points at discharge as sarcopenia. Results: The median age of the total of 23 patients was 59 years (interquartile range (IQR): 47−67), 73.9% were male, and the median PaO2/FiO2 at admission was 172.0 (IQR: 123.0−209.0). All physical function and ADL parameters were significantly improved from the time of admission to discharge (p = 0.014 for the MRC score and p < 0.001 for all others). Moreover, SPPB at discharge significantly correlated with WBC (Spearman’s rho = −0.473, p = 0.041), C-reactive protein (Spearman’s rho = −0.468, p = 0.044), and exhibited a significant trend with PaO2/FiO2 (Spearman’s rho = 0.429, p = 0.067) and age (Spearman’s rho = 0.409, p = 0.083). Although the median Barthel index at discharge was 90 points, 47% of patients had sarcopenia as defined by an SPPB of <9 points. Conclusions: Early rehabilitation for patients with severe COVID-19 improved physical function and ADLs during hospitalization. However, 47% of patients had the same level of sarcopenia at discharge.

Indexed as

activities of daily livingCOVID-19rehabilitationsarcopenia

Identifiers

PMID36362805
PMCPMC9654044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.